Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F18%3A10375419" target="_blank" >RIV/00064203:_____/18:10375419 - isvavai.cz</a>

Výsledek na webu

<a href="https://doi.org/10.1111/dom.13028" target="_blank" >https://doi.org/10.1111/dom.13028</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/dom.13028" target="_blank" >10.1111/dom.13028</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide

Popis výsledku v původním jazyce

The aim was to determine the effects of dulaglutide, a synthetic once-weekly, injectable human glucagon-like peptide 1 analogue that lowers blood glucose, body weight, appetite and blood pressure, on cardiovascular outcomes. People with type 2 diabetes, aged 50years, with glycated haemoglobin (HbA1c) 9.5%, and either a previous cardiovascular event, evidence of cardiovascular disease or 2 cardiovascular risk factors were randomly allocated to a weekly subcutaneous injection of either dulaglutide (1.5mg) or placebo and followed within the ongoing Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial every 3 to 6months. The primary cardiovascular outcome is the first occurrence of the composite of cardiovascular death or non-fatal myocardial infarction or non-fatal stroke. Secondary outcomes include each component of the primary composite cardiovascular outcome, a composite clinical microvascular outcome comprising retinal or renal disease, hospitalization for unstable angina, heart failure requiring hospitalization or an urgent heart failure visit, and all-cause mortality. Follow-up will continue until the accrual of 1200 confirmed primary outcomes. Recruitment of 9901 participants (mean age 66years, 46% women) occurred in 370 sites located in 24 countries over a period of 2years. The mean duration of diabetes was 10years, mean baseline HbA1c was 7.3%, and 31% had prior cardiovascular disease. The REWIND trial&apos;s international scope, high proportion of women, high proportion of people without prior cardiovascular disease and inclusion of participants whose mean baseline HbA1c was 7.3% suggests that its cardiovascular and safety findings will be directly relevant to the typical middle-aged patient seen in general practice throughout the world.

Název v anglickém jazyce

Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide

Popis výsledku anglicky

The aim was to determine the effects of dulaglutide, a synthetic once-weekly, injectable human glucagon-like peptide 1 analogue that lowers blood glucose, body weight, appetite and blood pressure, on cardiovascular outcomes. People with type 2 diabetes, aged 50years, with glycated haemoglobin (HbA1c) 9.5%, and either a previous cardiovascular event, evidence of cardiovascular disease or 2 cardiovascular risk factors were randomly allocated to a weekly subcutaneous injection of either dulaglutide (1.5mg) or placebo and followed within the ongoing Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial every 3 to 6months. The primary cardiovascular outcome is the first occurrence of the composite of cardiovascular death or non-fatal myocardial infarction or non-fatal stroke. Secondary outcomes include each component of the primary composite cardiovascular outcome, a composite clinical microvascular outcome comprising retinal or renal disease, hospitalization for unstable angina, heart failure requiring hospitalization or an urgent heart failure visit, and all-cause mortality. Follow-up will continue until the accrual of 1200 confirmed primary outcomes. Recruitment of 9901 participants (mean age 66years, 46% women) occurred in 370 sites located in 24 countries over a period of 2years. The mean duration of diabetes was 10years, mean baseline HbA1c was 7.3%, and 31% had prior cardiovascular disease. The REWIND trial&apos;s international scope, high proportion of women, high proportion of people without prior cardiovascular disease and inclusion of participants whose mean baseline HbA1c was 7.3% suggests that its cardiovascular and safety findings will be directly relevant to the typical middle-aged patient seen in general practice throughout the world.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Diabetes, Obesity &amp; Metabolism

ISSN

1462-8902

e-ISSN

—

Svazek periodika

20

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

8

Strana od-do

42-49

Kód UT WoS článku

000417482000005

EID výsledku v databázi Scopus

2-s2.0-85023614886